Focused On-demand Library for POU domain, class 3, transcription factor 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P49335

UPID:

PO3F4_HUMAN

Alternative names:

Brain-specific homeobox/POU domain protein 4; Octamer-binding protein 9; Octamer-binding transcription factor 9

Alternative UPACC:

P49335; B2RC71; Q5H9G9; Q99410

Background:

POU domain, class 3, transcription factor 4 (POU3F4), also known as Brain-specific homeobox/POU domain protein 4, Octamer-binding protein 9, and Octamer-binding transcription factor 9, plays a pivotal role in early neural development and maintains specific functions in a limited set of neurons in the adult brain. Its unique position in neural development pathways underscores its importance in cellular differentiation and maturation processes.

Therapeutic significance:

POU3F4 is directly implicated in Deafness, X-linked, 2, a condition characterized by conductive hearing loss and progressive sensorineural deafness. This association highlights the protein's critical role in auditory function and presents a targeted opportunity for therapeutic intervention in genetic hearing loss disorders.